-
Mashup Score: 0
Yehuda Handelsman, MD highlights insulin resistance’s role in cardiometabolic disease and introduces DCRM 2.0 as a global, multi-specialty care framework.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 0
The Boxed Warning is based on the FDA’s review of a postmarketing case of serious liver injury with fezolinetant reported to the FAERS database.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet-
ICYMI: The FDA has added a Boxed Warning to fezolinetant (Veozah) to highlight the known risk of “rare but serious” #liver injury associated with use of the medication, which is approved to treat hot flashes due to #menopause. Learn more: https://t.co/hIwfSitrUn https://t.co/gcRHFP7Epp
-
-
Mashup Score: 0Study Shows a U-Shaped Association Between HDL-C, Major Adverse Cardiovascular Events - 7 hour(s) ago
A study finds that individuals with low or high LDL cholesterol levels face a greater cardiovascular risk than those with medium levels.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet-
A study reveals a U-shaped link between HDL-C levels and major cardiovascular events in type 2 diabetes. Both low and high HDL-C levels pose greater risk than medium levels. https://t.co/KS6ce6sUio
-
-
Mashup Score: 0FDA News - 10 hour(s) ago
HCPLive is a comprehensive clinical news and information portal that provides physicians with up-to-date specialty and disease-specific resources designed to help them provide better care to patients. At HCPLive, you will find breaking news, video interviews with physician experts, in-depth conference coverage, finance and practice management updates, insight and analysis from physician contributors, and more.
Source: www.hcplive.comCategories: General Medicine News, General NewsTweet-
It was a busy Friday afternoon for @Regeneron last week, with approvals for CHAPLE disease and a trio of #ophthalmic conditions. Catch up on the latest #FDANews using our FDA News resource center: https://t.co/0pJN3WYqpG https://t.co/g8uMay3h2O
-
-
Mashup Score: 0
The ATEV therapy, named Symvess, provides revascularization when autologous vein graft or implantation of a synthetic graft is not feasible.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet-
The FDA has approved Symvess, an acellular tissue engineered vessel-tyod therapy for treating extremity vascular trauma and preventing limb loss. Read more: https://t.co/OrFev0CGAZ
-
-
Mashup Score: 2CagriSema Achieves 22.7% Weight Loss in Phase 3 REDEFINE 1 Trial - 16 hour(s) ago
CagriSema, a fixed dose of cagrilintide 2.4 mg and semaglutide 2.4 mg, achieved statistically significant weight loss after 68 weeks versus placebo.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet-
Topline data from REDEFINE 1 found CagriSema, a fixed-dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg, achieved superior weight loss versus placebo in adults with obesity or overweight. 🔗https://t.co/JA9E3FpCsN #ObesityManagement #PipelineNews https://t.co/zlt9K98d0D
-
-
Mashup Score: 2Belapectin Misses Primary Endpoint in Phase 3 MASH Cirrhosis, Portal Hypertension Trial - 19 hour(s) ago
The phase 2b/3 NAVIGATE trial missed its primary endpoint for the prevention of varices in patients with MASH cirrhosis and portal hypertension.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet-
Topline NAVIGATE results showed the trial of belapectin 2 mg/kg and 4 mg/kg for the treatment of patients with metabolic dysfunction-associated #steatohepatitis (MASH) cirrhosis and portal hypertension missed its primary endpoint. Learn more: https://t.co/lJqA4Vnvxa
-
-
Mashup Score: 0Hope on the Horizon: 2 Food Allergy Breakthroughs in 2024 - 1 day(s) ago
Kim, Sindher, Huffaker spoke with HCPLive about some of the year’s most important developments in the food allergy space, namely the approvals of omalizumab and neffy.
Source: www.hcplive.comCategories: General Medicine News, General NewsTweet-
The FDA approvals of #omalizumab (Xolair) and epinephrine nasal spray (#neffy) have made 2024 a big year in the food allergy space. We spoke with 3 allergists about the importance and impact of these approvals. View their responses here: https://t.co/uWqJOhRQzX #FoodAllergy
-
-
Mashup Score: 1
A phase 3 trial shows promising data for brexpiprazole with sertraline for PTSD symptoms ahead of the supplemental new drug application’s PDUFA date in February 2024.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet-
A phase 3 trial shows brexpiprazole + sertraline significantly reduced #PTSD symptoms in 10 days compared to placebo. Promising findings ahead of February 2025 PDUFA. https://t.co/LGWnpyvoqg
-
-
Mashup Score: 6
Tirzepatide’s approval marks the first and only prescription medicine available for adults with moderate-to-severe obstructive sleep apnea and obesity.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet-
🚨 The #FDA has approved tirzepatide (Zepbound;@EliLillyandCo) as the first prescription treatment for adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity. 🔗 https://t.co/H8cstOAA2M #Sleep #Obesity #FDANews https://t.co/RwGmdNMPn0
-
In a new interview at #WCIRDC2024, Yehuda Handelsman, MD, The Metabolic Institute of America (TMIOA), explored the updated DCRM 2.0, providing multi-specialty practice recommendation for patients with #diabetes, cardio, renal and metabolic diseases. 🔗https://t.co/KxCVFFfEit